Familial Hypocalciuric Hypercalcemia (FHH)

Jump to: What is FHH FHH vs hyperparathyroidism Diagnosis Management FAQ References

Medical information page by Alexander Shifrin, MD, Director of Endocrine Surgery, CentraState Medical Center. Based on the Fifth International Workshop (2022) and the European Society of Endocrinology consensus (2022).

What is familial hypocalciuric hypercalcemia (FHH)?

Familial hypocalciuric hypercalcemia (also called benign familial hypercalcemia) is an inherited (autosomal dominant) condition with three main features: lifelong mildly high blood calcium, low calcium in the urine compared with the blood level, and a parathyroid hormone (PTH) that is normal or mildly high. It is rare, with estimates of 1 in 10,000 to 1 in 100,000 people.

It is caused by a loss-of-function change in a gene that controls how the body senses calcium. The parathyroid glands and kidneys then read the calcium level as lower than it is, so the blood calcium is held at a higher set point.

Type Gene Notes
FHH1 CASR (calcium-sensing receptor) Most common type, about 60% of patients
FHH2 GNA11 Very rare
FHH3 AP2S1 Often with other features, such as lower bone density in some patients

Babies who inherit a changed gene from both parents (homozygous) can develop a rare, severe form called neonatal severe hyperparathyroidism.

FHH versus primary hyperparathyroidism

FHH matters because it can look just like primary hyperparathyroidism (PHPT) on a simple blood test: high calcium, with a PTH that is not suppressed, and usually normal kidney function. Telling them apart is important because parathyroid surgery cures most PHPT but does not correct FHH.

Feature FHH Primary hyperparathyroidism
Cause Inherited calcium-sensing gene change Overactive parathyroid gland(s), usually one adenoma
Blood calcium Mildly high, lifelong, from childhood High; often discovered in adulthood
PTH Normal or mildly high High or inappropriately normal
Urine calcium Low (calcium-creatinine clearance ratio usually under 0.01) Normal or high (ratio usually over 0.02)
Family history Often other relatives with high calcium Usually none (except in inherited syndromes)
Kidney stones, bone loss Not more than the general population More common
Bone density Typically normal (Z-score), with slightly higher bone turnover Often reduced
Vitamin D 25-hydroxyvitamin D normal; 1,25-dihydroxyvitamin D may be slightly high Varies
Does surgery help? No. Calcium stays high after parathyroidectomy. Yes, in most patients

How FHH is diagnosed

1. Confirm
High calcium and PTH on repeat tests
→
2. Urine
24-hour calcium and creatinine; calcium-creatinine clearance ratio
→
3. Family
Calcium in parents, siblings and children
→
4. Gene test
CASR, GNA11, AP2S1
Calcium-creatinine clearance ratio What it suggests
Below 0.01 Suggests FHH
0.01 to 0.02 Gray zone; genetic testing helps
Above 0.02 Makes FHH very unlikely; points to hyperparathyroidism
  • The 0.01 cut-off is only a screening tool. It misses some patients with FHH and some patients with hyperparathyroidism fall below it.
  • The European consensus recommends genetic testing in everyone with suspected FHH. A negative result does not rule FHH out, so those patients should have ongoing follow-up.
  • FHH and hyperparathyroidism can, rarely, occur in the same person.

Other causes of high calcium to consider: primary hyperparathyroidism (the main one), thiazide diuretics (which lower urine calcium), lithium, and cancer-related high calcium. See high calcium (hypercalcemia).

Management

FHH is lifelong but benign. Most patients have no symptoms and need no treatment. The main goals are to make the right diagnosis, avoid unnecessary parathyroid surgery and repeated testing, and test relatives. Calcium and PTH are simply monitored. Rare problems, such as pancreatitis and calcium deposits in joints, have been reported.

Why the diagnosis matters: Calcium stays high after parathyroid surgery in FHH, even after removing most of the parathyroid tissue. Patients with FHH are generally advised not to have parathyroidectomy. Be sure the diagnosis is settled before any operation is considered.

This page is for information. Dr. Shifrin does not treat FHH. If your tests turn out to show primary hyperparathyroidism instead, he evaluates and operates on that condition: call (732) 792-5003 or request a consultation.

Frequently asked questions

What is familial hypocalciuric hypercalcemia (FHH)?

FHH is an inherited condition in which calcium in the blood is mildly high for life, while calcium in the urine is low. It is caused by a change in a gene that helps the body sense calcium (most often CASR). It is usually harmless.

Why does FHH matter?

Because it looks like primary hyperparathyroidism on a basic blood test: high calcium and a PTH that is not low. The two are treated very differently, and parathyroid surgery does not fix FHH.

How do doctors tell them apart?

With a 24-hour urine collection (calcium and creatinine), a family history, and a genetic test. The urine calcium is low in FHH and normal or high in hyperparathyroidism.

Does a normal gene test rule out FHH?

No. Not every gene change has been found, so a negative test does not exclude FHH. The European consensus advises continued follow-up in these patients.

Does FHH cause kidney stones or bone loss?

Not more than in the general population. Bone density is typically normal. Rare cases of pancreatitis and joint calcium deposits have been reported.

Does FHH need an operation?

No. Calcium stays high after even a large parathyroid operation, so surgery is generally not advised. The goal is to be sure of the diagnosis first.

Should my relatives be tested?

Yes. Each child of an affected parent has a 50% chance of inheriting the gene change. Testing family members confirms the diagnosis, avoids repeated work-ups and unnecessary surgery, and identifies the rare risk to newborns when both parents carry a change.

References

  1. Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293-2314. doi:10.1002/jbmr.4677
  2. Kamenicky P, Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, et al; 2021 PARAT Working Group. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2022;186(2):R33-R63.
  3. Varghese J, Rich T, Jimenez C. Benign familial hypocalciuric hypercalcemia. Endocr Pract. 2011;17(Suppl 1):13-17.
  4. Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes. 2011;18(6):359-370.

This page is for general education and does not replace a medical evaluation.